CN1324367A - 环状前塞波素衍生肽及其应用 - Google Patents

环状前塞波素衍生肽及其应用 Download PDF

Info

Publication number
CN1324367A
CN1324367A CN99812627A CN99812627A CN1324367A CN 1324367 A CN1324367 A CN 1324367A CN 99812627 A CN99812627 A CN 99812627A CN 99812627 A CN99812627 A CN 99812627A CN 1324367 A CN1324367 A CN 1324367A
Authority
CN
China
Prior art keywords
amino acid
peptide
acid
hydrophobic amino
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99812627A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·E·赖特
约翰·S·奥布赖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myelos Corp
Original Assignee
Myelos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myelos Corp filed Critical Myelos Corp
Publication of CN1324367A publication Critical patent/CN1324367A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN99812627A 1998-08-28 1999-08-20 环状前塞波素衍生肽及其应用 Pending CN1324367A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9835998P 1998-08-28 1998-08-28
US60/098,359 1998-08-28

Publications (1)

Publication Number Publication Date
CN1324367A true CN1324367A (zh) 2001-11-28

Family

ID=22268937

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99812627A Pending CN1324367A (zh) 1998-08-28 1999-08-20 环状前塞波素衍生肽及其应用

Country Status (13)

Country Link
EP (1) EP1105420A1 (https=)
JP (2) JP4528443B2 (https=)
KR (1) KR20010079695A (https=)
CN (1) CN1324367A (https=)
AU (1) AU751034B2 (https=)
BR (1) BR9913490A (https=)
CA (1) CA2341810A1 (https=)
CZ (1) CZ2001655A3 (https=)
HU (1) HUP0103265A3 (https=)
IL (1) IL141586A0 (https=)
PL (1) PL204359B1 (https=)
WO (1) WO2000012553A1 (https=)
ZA (1) ZA200102489B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
CN103275187A (zh) * 2013-06-14 2013-09-04 四川科伦新光生物科技开发有限公司 一种镇痛肽fi及其基因和应用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
IL141586A0 (en) * 1998-08-28 2002-03-10 Myelos Corp Cyclic prosaposin-derived peptide and uses thereof
AUPQ084899A0 (en) * 1999-06-08 1999-07-01 University Of Melbourne, The Neurotrophin agonists
IL137820A (en) * 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide
ES2641272T3 (es) 2006-04-28 2017-11-08 Children's Hospital Medical Center Composiciones que comprenden proteínas o polipéptidos fusogénicos derivados de la prosaposina para aplicación en sistemas de suministro de fármacos transmembrana
JP5253402B2 (ja) * 2006-10-20 2013-07-31 チルドレンズ ホスピタル メディカル センター 自発的に形成する楕円体の単層リン脂質小胞
WO2016172409A1 (en) 2015-04-23 2016-10-27 The Procter & Gamble Company Delivery of surfactant soluble anti-dandruff agent
MX379907B (es) 2016-03-03 2025-03-11 Procter & Gamble Composicion anticaspa en aerosol.
WO2018075846A1 (en) 2016-10-21 2018-04-26 The Procter & Gamble Company Concentrated shampoo dosage of foam designating hair conditioning benefits
BR112019007682B1 (pt) 2016-10-21 2022-08-16 The Procter & Gamble Company Produtos de xampu compactos estáveis com baixa viscosidade e agente redutor de viscosidade
EP3528896A1 (en) 2016-10-21 2019-08-28 The Procter & Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
CN109862944A (zh) 2016-10-21 2019-06-07 宝洁公司 用于以最佳制剂空间递送消费者所需的剂型体积和表面活性剂量的泡沫剂型
EP3528774A1 (en) 2016-10-21 2019-08-28 The Procter and Gamble Company Concentrated shampoo dosage of foam designating hair volume benefits
EP3528894A1 (en) 2016-10-21 2019-08-28 The Procter and Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
CN109843383A (zh) 2016-10-21 2019-06-04 宝洁公司 用于在最佳制剂空间中递送消费者期望的剂量体积、表面活性剂量和头皮健康剂量的泡沫剂型
US11141370B2 (en) 2017-06-06 2021-10-12 The Procter And Gamble Company Hair compositions comprising a cationic polymer mixture and providing improved in-use wet feel
US11679073B2 (en) 2017-06-06 2023-06-20 The Procter & Gamble Company Hair compositions providing improved in-use wet feel
US11224567B2 (en) 2017-06-06 2022-01-18 The Procter And Gamble Company Hair compositions comprising a cationic polymer/silicone mixture providing improved in-use wet feel
MX388495B (es) 2017-10-10 2025-03-20 Procter & Gamble Composición de champú compacto que contiene surfactantes libres de sulfato.
CN111278418A (zh) 2017-10-10 2020-06-12 宝洁公司 具有基于氨基酸的阴离子表面活性剂和阳离子聚合物的致密型洗发剂组合物
CN111278416A (zh) 2017-10-10 2020-06-12 宝洁公司 含低无机盐的无硫酸盐个人清洁组合物
EP3694479B1 (en) 2017-10-10 2026-01-14 The Procter & Gamble Company A method of treating hair or skin with a personal care composition in a foam form
EP3727323B1 (en) 2017-12-20 2026-04-29 The Procter & Gamble Company Clear shampoo composition containing silicone polymers
US11318073B2 (en) 2018-06-29 2022-05-03 The Procter And Gamble Company Low surfactant aerosol antidandruff composition
US12226505B2 (en) 2018-10-25 2025-02-18 The Procter & Gamble Company Compositions having enhanced deposition of surfactant-soluble anti-dandruff agents
CN114746153A (zh) 2019-12-06 2022-07-12 宝洁公司 具有增强头皮活性物质沉积的不含硫酸盐的组合物
CN115151310B (zh) 2020-02-27 2024-12-20 宝洁公司 功效和美观性增强的含硫去头皮屑组合物
CA3198853A1 (en) 2020-11-23 2022-05-27 The Procter & Gamble Company Personal care compositions free of sulfated surfactants
MX2023005963A (es) 2020-12-04 2023-06-07 Procter & Gamble Composiciones para el cuidado del cabello que comprenden materiales de reduccion del mal olor.
US11771635B2 (en) 2021-05-14 2023-10-03 The Procter & Gamble Company Shampoo composition
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants
CA3235522A1 (en) 2021-12-09 2023-06-15 The Procter & Gamble Company Sulfate free personal cleansing composition comprising effective preservation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
IL141586A0 (en) * 1998-08-28 2002-03-10 Myelos Corp Cyclic prosaposin-derived peptide and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
CN103275187A (zh) * 2013-06-14 2013-09-04 四川科伦新光生物科技开发有限公司 一种镇痛肽fi及其基因和应用
CN103275187B (zh) * 2013-06-14 2014-10-29 四川合泰新光生物科技有限公司 一种镇痛肽fi及其基因和应用

Also Published As

Publication number Publication date
AU751034B2 (en) 2002-08-08
WO2000012553A1 (en) 2000-03-09
JP2010150272A (ja) 2010-07-08
HUP0103265A2 (hu) 2002-02-28
AU5690599A (en) 2000-03-21
EP1105420A1 (en) 2001-06-13
KR20010079695A (ko) 2001-08-22
JP4528443B2 (ja) 2010-08-18
JP2002523518A (ja) 2002-07-30
CA2341810A1 (en) 2000-03-09
CZ2001655A3 (cs) 2001-11-14
IL141586A0 (en) 2002-03-10
ZA200102489B (en) 2002-06-04
BR9913490A (pt) 2001-09-25
HUP0103265A3 (en) 2002-09-30
PL204359B1 (pl) 2010-01-29
PL346346A1 (en) 2002-02-11

Similar Documents

Publication Publication Date Title
CN1324367A (zh) 环状前塞波素衍生肽及其应用
AU734566B2 (en) Methods of alleviating neuropathic pain using prosaposin-derived peptides
US5703045A (en) Treating disorders by application of insulin-like growth factors and analogs
CA2058443C (en) Treating disorders by application of insulin-like growth factors and analogs
CN1452492A (zh) 神经保护肽
WO1997015593A1 (en) Neurotrophin antagonists
JP2002500161A (ja) 神経栄養性および鎮痛性のレトロインバースペプチド
WO1998039357A1 (en) Method of alleviating neuropathic pain
US6723699B1 (en) Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) Treating disorders by application of insulin-like growth factors and analogs
WO1998042746A9 (en) Synthetic saposin c-derived neurotrophic peptides
WO1998042746A2 (en) Synthetic saposin c-derived neurotrophic peptides
AU2002300005B2 (en) Method of alleviating neuropathic pain
JP2002544120A (ja) 逆・反転化プロサポシン由来ポリペプチドおよびその使用
MXPA01001966A (en) Cyclic prosaposin-derived peptides and uses thereof
MXPA98007245A (en) Methods to alleviate neuropathic pain using peptides derived from prosapos
HK1017612A (en) Treating disorders by application of insulin-like growth factors and analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication